Health Care Distributors

CD&R and McKesson have agreed to acquire Option Care Health for $32.05 per share, valuing the company at approximately $5.8 billion including debt, sending OPCH shares up 34% in early trading on Tuesday. Under the definitive agreement, CD&R will take a majority stake of approximately 51% in Option Care Health, while McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. Option Care Health will continue to operate as a separate company under its existing management team. Following the closing of the transaction, McKesson intends to account for its minority interest using the equity method of accounting, recording its share of Option Care Health's net income or loss in Other Income, net.

Cardinal Health announced in October 2026 that it had entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, maintaining the current scope of distribution services. The long-dated extension reinforces the durability of Cardinal Health's core distribution relationships and underscores the importance of scale partnerships in its business model. The company's narrative projects $297.6 billion in revenue and $3.0 billion in earnings by 2029, requiring 5.4% yearly revenue growth and an earnings increase of about $1.3 billion from $1.7 billion today. The extended CVS agreement supports that core distribution pillar but does not directly change the near-term focus on product quality risks from the levothyroxine and Webcol recalls, or cost pressure in the Global Medical Products and Distribution segment. The most relevant recent announcement alongside the CVS extension is Cardinal Health's August 2026 unsecured US$4.0 billion revolving credit agreement through 2031, which refreshes its funding flexibility and gives the company financial room to keep investing in automation, specialty distribution and at-home solutions.

Dr. Wirot Wasusuttikulkan, Chief Executive Officer of SMD Rise Public Company Limited, or SMD100, informed the Stock Exchange that the company's board meeting on October 2, 2026 approved the establishment of a new subsidiary to provide medical diagnostic imaging technology services in Thailand, covering X-ray, Ultrasound, CT Scan, PET/CT, MRI, radiation therapy, and digital health solutions, serving hospitals and related project customers. The new subsidiary is named SMD Remag (Thailand) Company Limited, with registered capital of 10 million baht, in which SMD100 holds 51% and Remag Group (Thailand) Company Limited holds 49%. The company expects to begin recognizing revenue from this business in the second quarter of 2027, using the company's working capital as the funding source for the establishment. At the same time, the meeting also approved the dissolution of SMD Pharmatics Company Limited, a wholly owned subsidiary that imports and distributes automated medication dispensing systems and related equipment and provides full installation and system integration services, due to financial performance that did not meet targets. The dissolution does not significantly affect the company's operations or financial position.

SMD Rise Public Company Limited, or SMD, informed the Stock Exchange of Thailand that its board of directors, at its 6/2569 meeting on 2 October 2569, approved the establishment of a new subsidiary named SMD REMAC (Thailand) Company Limited with registered capital of 10 million baht, divided into 100,000 ordinary shares at a par value of 100 baht each. SMD will hold 51% and REMAC Group (Thailand) Company Limited will hold 49%. The new company will provide medical diagnostic services using imaging technology in Thailand, covering X-ray, Ultrasound, CT Scan, PET/CT, MRI, radiotherapy, and digital health solutions, serving hospitals and related project customers. The company expects SMD REMAC to begin generating revenue in the second quarter of 2570, using the company's working capital as the funding source for the establishment. The transaction does not constitute a connected transaction and is not a significant transaction under the criteria of the Capital Market Supervisory Board. In addition, the board meeting approved the dissolution of SMD Pharmaceutics Company Limited, a wholly owned subsidiary in which SMD holds 100%, which operates the import and distribution of automated drug dispensing systems and related equipment and provides turnkey system installation services, because its financial performance did not meet targets.

Cardinal Health has extended its drug distribution agreement with CVS Health through June 2032, sending its shares up 3.7% in Thursday trading. The pharmaceutical distributor said it entered into a binding Letter of Intent to extend the existing distribution agreement through June 30, 2032, maintaining the current scope of distribution services. "We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers," said Jason Hollar, CEO of Cardinal Health. In connection with the contract renewal, Cardinal Health reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, and maintained its long-term non-GAAP EPS growth rate guidance of 12% to 14%. The company said further updates may be provided during its upcoming first quarter earnings call on November 5, 2026.

McKesson Corporation announced it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032. The Irving, Texas-based company said the extension builds on a relationship of more than 25 years, according to chair and chief executive officer Brian Tyler. McKesson is reaffirming its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth rate of 13% to 16%. Further updates will be provided during the company's second quarter fiscal 2027 earnings call on November 4, 2026. The company cautioned that the deal remains an agreement in principle and that risks include possible delays in signing a definitive contract, a failure to sign one, or not realizing all expected financial and operational benefits.

Cardinal Health announced it has entered into a binding Letter of Intent to extend its existing pharmaceutical distribution agreement with CVS Health through June 30, 2032, continuing the current scope of distribution services. "We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers," said Cardinal Health CEO Jason Hollar. In connection with the renewal, Cardinal Health reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, along with its long-term non-GAAP EPS growth rate guidance of 12% to 14%. The company said further updates may be provided during its upcoming first quarter earnings call on November 5, 2026.

PHC Holdings, which manufactures medical-related equipment, said on the 1st that it has received a non-binding initial acquisition proposal from Toho Holdings, a major pharmaceutical wholesaler. The announcement followed a report the previous day, and Toho Holdings also said it is "considering the matter mentioned in the article," though it said no decision has been made at this point. According to a Bloomberg report on September 30, Toho Holdings aims to acquire all shares through a tender offer, with the acquisition amount expected to exceed 200 billion yen. Domestic investment funds also showed interest in acquiring PHC, but Toho is currently the only buyer candidate in concrete acquisition talks. PHC's largest shareholder is the U.S. investment firm KKR, which holds about 38 percent. According to the report, PHC and KKR have each hired financial advisors and have been seeking a buyer for PHC in line with KKR's exit.

McKesson raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00, implying 15-17% growth at the midpoint, after first-quarter revenues rose 8% to $105.4 billion and adjusted EPS climbed 20% to $9.93. The oncology and multispecialty segment drove much of the momentum, with revenues up 33% to $14.2 billion and operating profit up 41%, or roughly 24% revenue growth excluding the Core Ventures acquisition, and management now expects 14.5-18.5% segment revenue growth for fiscal 2027. North American Pharmaceutical generated $15 billion of GLP-1 distribution revenues in the quarter, more than 14% of total revenues, up approximately 24% year over year and 13% sequentially. Offsetting those gains, the medical-surgical solutions segment posted just 4% revenue growth to $2.8 billion while operating profit fell 20% to $195 million, and management guided to only 1-6% revenue growth and flat-to-4% operating-profit growth for that unit in fiscal 2027. McKesson also flagged continued uncertainty from 340B reform and the IRA Part D framework, which is not scheduled to take effect until January 2028, while the Zacks Consensus Estimate for fiscal 2027 EPS has improved 3 cents to $44.64 over the past 30 days.

Renmintongtai announced after market close on September 29 that it recently received Civil Judgment No. 50, Civil First Instance, Harbin Intermediate People's Court, 2025, confirming that multiple construction contracts and agreements signed between the company and Heilongjiang Provincial No. 7 Construction Engineering Co., Ltd. are invalid, and ordering Provincial No. 7 Construction to return overpaid project funds of more than 55.18 million yuan, and to withdraw from and hand over the construction site of the Sanjing Women's Specialist Hospital complex project. The dispute began in 2014, when Provincial No. 7 Construction sued Sanjing Pharmaceutical for payment of 30 million yuan in project progress payments. In 2017, the company lost both the first and second trials, and in 2018, more than 32.55 million yuan was deducted from the company's account and enforcement was completed. In 2021, the Provincial High Court ruled to revoke the original first and second instance judgments and remanded the case for retrial. In 2023, the first retrial judgment dismissed Provincial No. 7 Construction's claims, but both parties appealed. In 2024, the case was again remanded to Harbin Intermediate People's Court for retrial, entering the first-instance stage of the second retrial. This judgment also orders Provincial No. 7 Construction to hand over project-related materials. The case acceptance fee for the main action of approximately 841,600 yuan shall be borne by Provincial No. 7 Construction. The project cost appraisal fee and the project quality and reinforcement appraisal fee totaling 1.555 million yuan shall be borne 60% by Provincial No. 7 Construction and 40% by the company. The announcement cautioned that the case is still in the first-instance stage of the second retrial, both parties have the right to appeal, and the final judgment result and its impact on the company's profits remain uncertain.

Henry Schein amended and restated its revolving credit facility, increasing total commitments to $1.25 billion and extending the termination date to September 19, 2031. The medical products distributor's shares traded at $86.37, up 0.98% over one day and 1.80% over seven days, though the 30-day return slipped 3.52% while the year-to-date return stands at 12.43%. The 1-year total shareholder return of 30.74% suggests investors have read the upgraded facility and a recent guidance raise as supportive of both growth plans and perceived risk. The most followed valuation narrative pegs fair value at $98.19, above the latest close, with the company expecting more than 50% of non-GAAP operating income to come from high-margin businesses such as Specialty Products, Technology, and private-label offerings. Risks to that case include scanner pricing pressure eroding equipment margins faster than expected or multi-year analyst forecasts proving too optimistic.

McKesson has raised its full-year adjusted earnings per share guidance, a move that comes as its share price slipped 1.2% and trailed the broader market. The stock has fallen 3.95% over the past 30 days, even after a 13.86% 90-day return and a 5.58% gain year to date, while total shareholder return stands at 18.50% over one year. The most followed narrative values McKesson at a fair value of $980.73 against a last close of $869.36, implying the stock is 11% undervalued, a view held by 61 investors. That story leans on the company's oncology ecosystem, including the US Oncology Network, PRISM and Precision Medicine Group, as a central driver of revenue mix and margin potential. Risks to the narrative include drug pricing pressure on already thin margins and higher costs and customer churn from a recent cyber incident.

Healthy Lead Public Company Limited, or HL, is preparing to expand into the pet health products market to capture the Pet Humanization trend, as pet owners increasingly treat their pets as family members. Supakorn Panthukanon, Chief Executive Officer of HL, said the company will source and distribute products in the supplement, vitamin, and pet medication categories to meet rising demand from pet owners, and as another channel to extend its customer base and create long-term growth opportunities. This move into the Pet Health market is part of HL's strategy to expand its health product portfolio, after the company accelerated business expansion in the second half of 2026 through both adding distribution channels and developing new products. Most recently, the company opened a new iCare branch on Phutthamonthon Sai 4 to increase service space and expand its customer base, while continuing to develop innovative products under the Prime brand, including Prime Immuliv, Prime G3, as well as products that enhance the absorption of key active ingredients, or Bioavailability Enhancers, and products in the skincare group. Meanwhile, herbal products under the Q brand have won international awards, reflecting its approach to product development aimed at expanding the product portfolio and adding diversity to the business. The company views the pet health market as having growth potential in line with the Pet Humanization trend, which is leading pet owners to spend more on healthcare, disease prevention, and improving their pets' quality of life. It is therefore another market that HL plans to use as a base to extend revenue and create future growth opportunities.

HL is pressing ahead with full force to expand its customer base in the second half of 2026 by opening a new iCare branch at Phutthamonthon Sai 4, while accelerating the development of innovative products under the Prime brand, a line of health-care supplements including Prime Immuliv, Prime G3 and an absorption-enhancing product, as well as skin-care products and herbal products under the Q brand that have won international awards. The company is also moving into the Pet Health market in line with the pet humanization trend by sourcing and distributing supplements, vitamins and medicines for pets. Meanwhile, PTG has received the Human Rights Awards 2026 at the outstanding level in the large business organisation category for the second consecutive year. TMAN, for its part, has opened the Heaven Herb factory in Pathum Thani province, showcasing the potential of a production base driven by modern technology, with a target of creating 15 new products within five years to meet global demand and the growing longevity trend, while continuing to transform the factory with an investment budget of 50 million baht per year to help drive Thailand toward becoming a Global Wellness Hub.

Healthy Lead Public Company Limited, or HL, is pushing aggressively to expand its customer base in the second half of 2026, opening a new iCare branch on Phutthamonthon Sai 4 while accelerating development of innovative products under the Prime brand, its health-care supplement line. These include Prime Immuliv, Prime G3, a bioavailability enhancer product, as well as skin-care products and herbal products under the Q brand that have won international awards. Chief Executive Officer Supakorn Phanthukanon is pursuing an aggressive push into the Pet Health market to capture the pet humanization trend by sourcing and distributing supplements, vitamins, and medicines for pets, meeting the needs of owners who are increasingly focused on their pets' health and quality of life. It is another high-potential market that HL is preparing to build on to create long-term growth opportunities.

McKesson is expected to post earnings of $10.72 per share for the current quarter, a year-over-year change of +8.7%, with the Zacks Consensus Estimate rising +1.4% over the last 30 days. The consensus earnings estimate of $44.64 for the current fiscal year indicates a year-over-year change of +14.1% and has remained unchanged over the last 30 days, while the next fiscal year's consensus estimate of $49.83 points to a change of +11.6%. The consensus sales estimate of $110.14 billion for the current quarter points to a year-over-year change of +6.8%, and the $429.09 billion and $459.25 billion estimates for the current and next fiscal years indicate changes of +6.4% and +7%, respectively. McKesson reported revenues of $105.38 billion in the last reported quarter, a year-over-year change of +7.7%, with EPS of $9.93 versus $8.26 a year ago, beating the Zacks Consensus Estimate of $104.39 billion by +0.95% on revenue and posting an EPS surprise of +5.19%. The stock carries a Zacks Rank #3 (Hold) and a Zacks Value Style Score of B, indicating it trades at a discount to its peers.

Cencora raised its full-year adjusted EPS outlook and announced a US$1b buyback after a stronger fiscal third quarter, and said it plans to brief investors at two New York healthcare conferences. The upbeat earnings message has not lifted the shares in the near term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78, while the 90 day share price return stands at 13.82%, the 1 year total shareholder return at 7.28% and the 5 year total shareholder return at 165.36%. The most followed narrative values Cencora at a fair value of $372.58, above the recent $308.78 close and below the $369.31 analyst price target, built on a 7.24% discount rate and assumptions of revenue rising to $394.5b and earnings reaching $3.4b by 2029, with the shares trading on a 24.3x P/E at that point. That narrative also weighs the added debt from OneOncology alongside recent acquisitions such as Retina Consultants of America, and warns the story could change quickly if lower fee biosimilars keep squeezing margins or if international logistics weakness drags on group profitability longer than analysts expect.

Cardinal Health said it expects adjusted earnings per share to grow 13% to 15% in fiscal 2027, driven primarily by operating-income growth across its three reporting segments and five operating businesses. Speaking at the Morgan Stanley Global Healthcare Conference, CEO Jason Hollar said the company reiterated its longer-term EPS growth target of 12% to 14% and plans $1 billion in share repurchases, with lower interest expense and a slightly higher expected tax rate among below-the-line factors. Within Pharmaceutical and Specialty Solutions, generic-drug volume is expected to grow slightly above the usual 2% to 3% range, while specialty growth is expected to approach a double-digit rate after expanding 25% in fiscal 2026, and BioPharma Solutions is targeting $1 billion in revenue by fiscal 2028 from $550 million in fiscal 2025. Cardinal Health expects its other segment to deliver 15% to 18% adjusted operating-income growth in fiscal 2027, with about 2 percentage points from the Strive Medical acquisition and a small late-year contribution from AdaptHealth's diabetes business. In Global Medical Products and Distribution, the company absorbed a $450 million tariff impact in fiscal 2026 and mitigated about two-thirds through sourcing and other operating actions, and Hollar said the year-end renewal of the CVS distribution contract rests on a very strong relationship.

Cardinal Health expects growth to normalize in fiscal 2027 after fiscal 2026 delivered double-digit earnings growth in all five operating segments, CEO Jason Hollar said at a Baird event. Hollar said the prior year's outperformance was driven by strong healthcare utilization, specialty growth, new customer wins, acquisitions and operational execution, and that unusually strong specialty growth and customer onboarding will be less pronounced in fiscal 2027. Cardinal's specialty business grew 25% in fiscal 2026, and the company is expanding its specialty and at-home strategy through three managed-services organization platforms focused on oncology, urology and gastroenterology, plus bolt-on acquisitions, including four completed in the most recent quarter. The Strive Medical acquisition has closed, while the purchase of AdaptHealth's diabetes business is expected to close in the second half of fiscal 2027, expanding Cardinal's continuous glucose monitoring presence; Hollar noted only 35% of people eligible for a CGM through insurance coverage actually have one. Cardinal plans to add three more automated distribution centers for small-parcel shipping of higher-value at-home products, and Hollar said cash flow was strong in fiscal 2026, putting the company about 90% of the way toward its previously announced $10 billion objective.

Cencora reported fiscal third-quarter results on August 5, with revenue up 5.1% to $84.8 billion and adjusted earnings per share up 12.0% to $4.48, while management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion of its own stock during the quarter, completing in one quarter the buybacks it had expected to finish by the close of calendar 2026, and the board declared a $0.60 quarterly dividend payable August 31 to holders of record on August 14. Adjusted operating income rose 17.0% while revenue grew only 5.1%, helped by adjusted gross profit that jumped 23.2% as adjusted gross margin widened 61 basis points to 4.16%, with the February OneOncology acquisition lifting margins in the US business. US Healthcare Solutions grew operating income 15.9%, while International Healthcare Solutions operating income rose 20.8%. Adjusted operating expenses jumped 26.8% because OneOncology brought expenses along with its profits, net interest expense rose $58.9 million from a year earlier, and lower-margin GLP-1 drugs plus an oncology customer lost in 2025 and lower sales to a large mail order customer weighed on US revenue.

Cencora is using artificial intelligence to roughly halve the time it takes to make some medical treatment decisions, according to the company's global chief data and information officer, Pawan Verma. Speaking with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit, Verma described a retinal oncology use case in which doctors analyze large volumes of imaging data to determine treatment. He said Cencora is helping cut a decision process that can take 30 to 90 days roughly in half, speeding access to treatment.

Alluvium Asset Management raised its stake in McKesson Corporation to 6.8% of the Conventum – Alluvium Global Fund, according to the fund's second-quarter 2026 investor letter. The fund said McKesson, the Irving, Texas-based drug distributor, fell 12.6% in the quarter even though its full-year results came in perfectly in line with expectations, and management gave strong guidance for next year's earnings while reiterating 13%-16% long-term growth expectations. After feeding those numbers through its model, Alluvium said its valuation rose 18%, and with the share price trading below that level it bought a little more. McKesson closed at $899.56 per share on September 15, 2026, returning 5.37% over the past month and 29.95% over the past 52 weeks, with a market capitalization of $106.21 billion and a trading range of $687.68 to $999.00. The fund itself declined 1.4% in EUR terms, 2.2% in USD terms and 3.9% in AUD terms in the quarter, a period it described as a sharp shift from geopolitical uncertainty and oil market volatility to an equity rally led by semiconductor companies.

McKesson raised its full-year EPS guidance, projecting approximately 13%–15% growth, or 15%–17% excluding certain prior-year items. The company also outlined plans to rebrand its Medical-Surgical unit as Wellverse, with a potential IPO targeted for the second half of 2027. Alongside that, McKesson has a pending acquisition of Precision Medicine Group to expand oncology and biopharma-services capabilities, subject to regulatory approval. The combination of upgraded earnings expectations, portfolio reshaping around higher-value oncology and biopharma services, and the potential separation of Wellverse marks a meaningful shift in how McKesson positions its future business mix and profit drivers.

McKesson raised its full-year earnings-per-share guidance by $0.40 to a range of $44.20 to $45.00, implying growth of roughly 13% to 15%, or 15% to 17% after adjusting for the company's Norway exit and a prior-year gain on the sale of U.S. Oncology. Speaking at the Morgan Stanley Global Healthcare Conference, Chief Financial Officer Kenny Cheung said three of the company's four reportable segments posted double-digit growth in the first quarter, led by Oncology & Multispecialty, which generated 33% reported revenue growth and approximately 41% adjusted operating profit growth, and Prescription Technology Solutions, which recorded approximately 9% revenue growth and 13% adjusted operating profit growth. Chief Executive Officer Brian Tyler said McKesson's pending acquisition of Precision Medicine Group fits its longstanding strategy of expanding oncology and biopharma-services capabilities, complementing the Sarah Cannon Research Institute, the Ontada data and analytics business and the U.S. Oncology Network, which now has roughly 3,400 providers; the deal remains subject to regulatory approvals and is expected to be accretive both strategically and financially. In North American Pharmaceutical, first-quarter revenue rose 5% and adjusted operating profit increased 19%, while the Medical-Surgical business, to be named Wellverse, reported 4% revenue growth and an approximately 20% year-over-year decline in adjusted operating profit, with McKesson still targeting an initial public offering exit in the second half of 2027 subject to market conditions. Tyler also said the company's distribution relationship with CVS has extended for more than 20 years, with the current contract running through June 2027, and that roughly one-third of McKesson's contracts typically come up for renewal each year.

Cardinal Health reported fourth-quarter fiscal 2026 adjusted earnings per share of $2.91, beating the Zacks Consensus Estimate by 20.3% and up 40% year over year, while quarterly revenues rose 6% to $63.67 billion but missed the consensus estimate by 2.9%. GAAP earnings per share in the quarter was $1.70 compared with $1.00 a year earlier, and full-year fiscal 2026 adjusted EPS was $11.26, up 37% from fiscal 2025, with full-year revenues of $254.25 billion, up 14%. Within the quarter, Pharmaceutical and Specialty Solutions revenues rose 6% to $58.85 billion with segment profit of $645 million, up 21%, while Global Medical Products and Distribution revenues fell 2% to $3.13 billion even as segment profit rose to $150 million from $70 million, and the Other segment, comprising Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics, posted revenues of $1.72 billion, up 7%, with profit of $183 million, up 14%. Cardinal Health raised its fiscal 2027 earnings guidance to adjusted earnings per share of $12.40 to $12.60, implying growth of 13% to 15% from adjusted fiscal 2026 results excluding the IEEPA tariff refund benefit, and guided Pharmaceutical and Specialty Solutions revenue growth of 3% to 5% with segment profit up 8% to 11%, Global Medical Products and Distribution revenue growth of 2% to 4% with segment profit of $200 million to $220 million, and Other segment revenue growth of 11% to 13% with segment profit up 15% to 18%.

McKesson is moving forward with its planned $2.25 billion acquisition of Precision Medicine Group, a deal that would expand its oncology and biopharma services. The company discussed the transaction during a presentation with Wells Fargo analyst Stephen Baxter, saying it would add clinical-trial capabilities, including biomarker-focused trials, and complement its existing assets like Sarah Cannon, Ontada, and the U.S. Oncology Network. Precision Medicine Group also brings a more established contract research organization, or CRO, capability focused on oncology, rare disease, immunology, and cell and gene therapy. McKesson's CFO, Kenny Cheung, said the company expects the deal to create incremental value for biopharma partners and will provide more details on earnings accretion as the transaction progresses. In the first quarter, McKesson's Oncology and Multi-Specialty segment saw revenue grow about 33% and adjusted operating profit rise about 41%, while the company reiterated plans to return roughly $5 billion to shareholders this year.

Healthlead Public Company Limited, or HL, is preparing to launch its Telepharmacy platform through an application operated by iCare Health Company Limited, aiming to elevate pharmacies into the digital era. Patients will be able to consult pharmacists remotely and receive medications delivered to their homes, in accordance with regulations permitted by the Food and Drug Administration (FDA). Additionally, HL has partnered with pharmaceutical delivery service CERO Win to support logistics, enhancing service standards. This development marks a significant step in integrating technology into the Health & Wellness business, with expectations for it to serve as a growth engine driving revenue in 2026 to a new record high, in line with targets.

Healthlead (HL) is set to launch its application service platform operated by iCare Health Company in the near future, in response to the Telepharmacy trend, following FDA approval for patients to legally consult pharmacists and receive medications at home. With logistics partner CERO Win enhancing delivery standards, this marks a significant step in integrating technology with the Health & Wellness business, increasing access to pharmaceutical services, and opening doors to new business opportunities in the future. The platform is expected to serve as a growth engine, supporting long-term expansion and driving this year's revenue to a new record high as planned.

Cencora reported third-quarter fiscal 2026 adjusted earnings per share of $4.48, beating the Zacks Consensus Estimate of $4.37 by 2.5%, and raised its full-year adjusted EPS guidance to $17.75-$17.95 from $17.70-$17.90. Revenues rose 5.1% year over year to $84.76 billion, slightly missing the consensus estimate of $84.89 billion, with growth driven by its U.S. Healthcare Solutions segment, which saw revenues increase 4.9% to $74.9 billion, and International Healthcare Solutions, which grew 5.9% to $7.7 billion. Adjusted operating income advanced 17% to $1.24 billion, and the company now projects adjusted operating income growth of 13-14% for the fiscal year. Since the earnings release, estimates have trended downward, and Cencora holds a Zacks Rank #3 (Hold).

Cencora raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks Consensus Estimate by 2.5%. Third-quarter revenues increased 5.1% to $84.76 billion, while adjusted operating income advanced 17% to $1.24 billion. Cencora lifted fiscal 2026 adjusted earnings guidance to $17.75-$17.95 per share from $17.70-$17.90, and narrowed adjusted operating income growth expectations upward to 13%-14% from 12%-14%, while maintaining consolidated revenue growth guidance of 4%-6%. U.S. Healthcare Solutions revenues rose 4.9% to $74.9 billion, with segment operating income up 15.9% to $966.2 million, driven by OneOncology and GLP-1 demand. International Healthcare Solutions revenues increased 5.9% to $7.7 billion, with operating income up 20.8% to $165.9 million. However, GLP-1 sales carry lower margins, and net interest expense increased 72% to $140.7 million due to debt from the OneOncology acquisition.

Jointown announced on August 31 that it plans to issue preferred shares to raise total proceeds of no more than 2.8 billion yuan. The funds raised will be used to repay bank loans and other interest-bearing liabilities, and to replenish working capital.

Shanghai Pharmaceuticals announced that its subsidiary Changzhou Pharmaceutical Factory has received a drug registration certificate for Ruxolitinib Phosphate Tablets from the National Medical Products Administration, with specifications of 5 mg, 15 mg, and 20 mg, classified as a Category 4 chemical drug. The drug is used to treat adult patients with intermediate or high-risk primary myelofibrosis and other myelofibrosis conditions, as well as graft-versus-host disease in patients aged 12 and older. It was jointly developed by Incyte and Novartis and launched in the United States in 2011. Changzhou Pharmaceutical Factory submitted its registration and marketing application in December 2024, with cumulative research and development investment of approximately 24.81 million yuan.

Jointown Pharmaceutical announced a preliminary plan for a 2026 private placement of preferred shares. The company intends to issue no more than 28 million preferred shares, raising total proceeds of up to 2.8 billion yuan. After deducting issuance expenses, the funds will be used to repay bank loans and other interest-bearing liabilities, as well as to supplement working capital. The placement will target no more than 200 qualified investors, with no preferential allotment to existing shareholders.

McKesson Corporation has agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion, as the healthcare company continues shifting its portfolio toward higher-growth businesses. Precision Medicine provides clinical research, laboratory testing, and commercialization services to biotechnology and pharmaceutical companies developing and launching new medicines. McKesson plans to integrate the company into its Oncology & Multispecialty segment, which generated $14.2 billion in revenue in fiscal 2026's first quarter, a 33% year-over-year increase. The acquisition represents just over 2% of McKesson's market capitalization, according to an analyst cited by Reuters, making it meaningful but not large enough to fundamentally alter the company's financial profile. The deal strengthens McKesson's exposure to clinical research, oncology, specialty care, and biopharma services, though execution risks remain in integrating the business and realizing synergies.